FY2025 Earnings Forecast for DVAX Issued By William Blair

Dynavax Technologies Co. (NASDAQ:DVAX) – Research analysts at William Blair dropped their FY2025 earnings estimates for shares of Dynavax Technologies in a research note issued to investors on Wednesday, May 7th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will earn $0.25 per share for the year, down from their previous estimate of $0.28. William Blair has a “Outperform” rating on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.32 per share.

Several other equities research analysts have also commented on the company. StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. JMP Securities decreased their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a research report on Wednesday. Finally, The Goldman Sachs Group lowered their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating on the stock in a research note on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $24.00.

Dynavax Technologies Stock Down 2.9 %

Shares of DVAX opened at $9.41 on Friday. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of 52.28 and a beta of 1.26. Dynavax Technologies has a 52 week low of $9.28 and a 52 week high of $14.63. The stock’s 50-day moving average price is $12.24 and its 200-day moving average price is $12.55. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.14). The business had revenue of $68.16 million for the quarter, compared to analyst estimates of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%.

Hedge Funds Weigh In On Dynavax Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. lifted its stake in Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 1,169 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Dynavax Technologies in the first quarter valued at approximately $30,000. Smartleaf Asset Management LLC boosted its stake in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 2,034 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Dynavax Technologies in the 4th quarter valued at $35,000. Finally, GAMMA Investing LLC lifted its holdings in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 1,457 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.